| Product NDC: | 65977-5025 |
| Proprietary Name: | Finasteride |
| Non Proprietary Name: | Finasteride |
| Active Ingredient(s): | 5 mg/1 & nbsp; Finasteride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 65977-5025 |
| Labeler Name: | Hetero Drugs Limited |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA090061 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20100607 |
| Package NDC: | 65977-5025-4 |
| Package Description: | 48 BOTTLE in 1 CONTAINER (65977-5025-4) > 500 TABLET in 1 BOTTLE |
| NDC Code | 65977-5025-4 |
| Proprietary Name | Finasteride |
| Package Description | 48 BOTTLE in 1 CONTAINER (65977-5025-4) > 500 TABLET in 1 BOTTLE |
| Product NDC | 65977-5025 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Finasteride |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20100607 |
| Marketing Category Name | ANDA |
| Labeler Name | Hetero Drugs Limited |
| Substance Name | FINASTERIDE |
| Strength Number | 5 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | 5-alpha Reductase Inhibitor [EPC],5-alpha Reductase Inhibitors [MoA] |